Analysts at Stifel Nicolaus started coverage on shares of GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $100.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 22.67% from the company’s current price.
A number of other analysts have also recently weighed in on GEHC. The Goldman Sachs Group assumed coverage on shares of GE HealthCare Technologies in a report on Thursday, May 30th. They set a “neutral” rating and a $87.00 target price for the company. Mizuho decreased their price objective on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Finally, Bank of America decreased their price objective on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $94.58.
Get Our Latest Research Report on GEHC
GE HealthCare Technologies Stock Performance
Shares of NASDAQ GEHC opened at $81.52 on Tuesday. The firm’s 50-day moving average price is $78.94 and its two-hundred day moving average price is $82.56. GE HealthCare Technologies has a 52-week low of $62.35 and a 52-week high of $94.50. The stock has a market capitalization of $37.21 billion, a P/E ratio of 23.84, a P/E/G ratio of 3.00 and a beta of 1.17. The company has a quick ratio of 0.83, a current ratio of 1.06 and a debt-to-equity ratio of 1.05.
GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.02. GE HealthCare Technologies had a net margin of 8.10% and a return on equity of 25.26%. The business had revenue of $4.84 billion for the quarter, compared to analyst estimates of $4.88 billion. During the same quarter last year, the business earned $0.92 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. As a group, sell-side analysts forecast that GE HealthCare Technologies will post 4.27 earnings per share for the current year.
Insider Activity
In other news, CTO Taha Kass-Hout sold 3,300 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the transaction, the chief technology officer now owns 67,300 shares in the company, valued at approximately $5,296,510. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other GE HealthCare Technologies news, CTO Taha Kass-Hout sold 3,300 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the transaction, the chief technology officer now directly owns 67,300 shares in the company, valued at $5,296,510. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jan Makela sold 66,955 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the completion of the transaction, the chief executive officer now directly owns 63,348 shares of the company’s stock, valued at $5,165,395.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,482 shares of company stock worth $7,369,137. 0.27% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On GE HealthCare Technologies
Several large investors have recently bought and sold shares of GEHC. Pathway Financial Advisers LLC acquired a new position in shares of GE HealthCare Technologies in the first quarter valued at approximately $25,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $30,000. BNP Paribas acquired a new position in shares of GE HealthCare Technologies in the first quarter valued at approximately $30,000. Sachetta LLC acquired a new position in GE HealthCare Technologies during the fourth quarter worth $31,000. Finally, Rise Advisors LLC boosted its holdings in GE HealthCare Technologies by 241.4% during the first quarter. Rise Advisors LLC now owns 338 shares of the company’s stock worth $31,000 after purchasing an additional 239 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.
About GE HealthCare Technologies
(Get Free Report)
GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.
Featured Articles
Receive News & Ratings for GE HealthCare Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GE HealthCare Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
link